EQRx
EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020 by Alexis Borisy with a mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company went public in 2021 through a SPAC merger with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development programs and was acquired by Revolution Medicines in an all-stock transaction. It was surfaced in the API Evangelist network as a portfolio-company lead (backed by a16z and GV); it never operated a public developer platform or API, and its web presence is no longer live.
EQRx is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Biotechnology, and Oncology.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API